the chart the chalice the chase, page-63

I don’t know how June cannot be deemed as anything BUT a significant month for ANP. Three possible big deals are either given the nod or they’re dismissed.

Is there any bigger value adding exercise for ANY company to obtain than moving from a possible to a confirmed deal. A sale is not a sale and an agreement is not an agreement until it’s finalised after all.

In the case of a small cap bio with their own IP and 3 drugs heading into trails with 2 free carried and the third a possible blockbuster tie-in all to be confirmed within 4 weeks it is obviously a big moment for the company and you’d have to be short a quid to not see it imv.

Going by the rerating ANP has been undergoing over the past 6 months the market shares the view that this is the stock that is going places soon. Those in the industry around the Asia-pacific region are eyeing up the antisense scene and watching developments closely. If economic times weren’t so grim we’d be over 10c by now imv. Once mipomersen is given the go ahead I’ll bet both ISIS and ANP will become a vessel of significant wealth creation for all involved… but how about we let the market speak for itself and forget the juvenile bickering on a public forum!

ISIS continues to tick boxes and receive substantial milestone payments for the same generational drugs as ANP... to say ANP wouldn’t receive their milestone payments because other ASX juniors haven’t in the past is foolhardy talk.

The same water tight agreements that ISIS adopts will be the same as ANP does.

Get with the program or get left behind


Good Luck!